Prostate cancer epidemiology

Archivos Espanoles de Urologia

Volumn 67, Issue 5, 2014, Pages 373-382

  Bello, Ana Plata ^a   Masip, Tomas Concepcion ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Active surveillance; Epidemiology; Prostate cancer

Indexed keywords

EVIDENCE BASED MEDICINE; HUMAN; MALE; PROSTATIC NEOPLASMS; RISK FACTOR;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84902789053     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Center M.M, Jemal J, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International Variation in Prostate Cancer Incidence and Mortality rates. Eur J Urol 2012; 61:1079-1092.
2. Siegel R, Naishadham D, Jenal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
4. Cózar JM, Miñana B, Gómez-Veiga F, Rodriguez-Antolin A, Villavicencio H, et al. Prostate cancer incidente and newly diagnosed patient profile in Spain 2010. BJU 2012;110(11):701-706.
5. Cózar JM, Miñana B, Gómez-Veiga F, Rodriguez-Antolin A, Villavicenvio H, Cantalapiedra A, et al. Registro nacional de cáncer de próstata 2010 en España. Actas Urol Esp 2013;37:12-19.
6. Granado S, Saá C, Quintás A. Situación epidemiológica del cáncer de próstata en España. Actas Urol Esp 2006; 30(6):574-582.
7. Scher HI, Isaac JT, Zelefsky MJ. Prostate Cancer. Clinical Oncology, 2nd ed. Edited by Abeloff MD, Armitage JO, Lichter AS, New York: Churchill Livingstone.
8. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63: 963-966.
9. Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 2011;71(10):1054-1063.
10. Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosedwith prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev 2010;19(10):2437-2444.
11. Powell IJ, Bock C, Ruterbisch J, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progresion and mortalitty disparity. J Urol 2010; 183(5):1792-1797.
12. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141(8):732-740.
13. Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, et al. Prostate cancer risk in U.S blacks and whites with a family history of cancer. Int J Cancer 1995;60(3):361-364.
14. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweeden, Denmark and Finland. N Engl J Med 2000;343(2):78-85.
15. Gronberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am J Epidemiol 1997;146(7):552-557.
16. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG. Segregation analises of 1476 population-based Australian familys affected by prostate cancer. Am J Hum Genet 2001;68(5):1207-1218.
17. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994;152:1484-1487.
18. Page WF, Braun MM, Partin Aw, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997;33(4):240-245.
19. Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002;110(2):122-129.
20. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potencial inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9(4):439-442.
21. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57(6):1194-1198.
22. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progresion. Urology 2001;57(1):199-204.
23. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67(4):1014-1019.
24. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68(4):901-911.
25. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2001;12(3):182-196.
26. Valeri A, Fournier G, Morin V, Morin JF, Drelon E, Mangin P, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer 2000; 86(6):883-887.
27. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72(1):1-12.
28. Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000;60(16):4513-4518.
29. Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, et al. Personal history of Prostate cancer and increased risk of incident Melanoma in the United States. J Clin Oncol 2013;31(35):4394-4399.
30. Jonsson BA, Bergh A, Stattin P, EmmanuelssonM, Grönberg H. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002;98(6):838-843.
31. Klein EA, Platz EA, Thompson IM. Epidemiología, etiología y prevención del cáncer de próstata. Urología Campbell-Walsh.2008, 9.edición. Tomo III:2854-2873.
32. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18(4):847-853.
33. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
34. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997;57(6):1020-1022.
35. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90(16):1225-1229.
36. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89(2):166-170.
37. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56(18):4108-4110.
38. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279(5350):563-566.
39. Fleshner N, BagnellPS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004.;171:S19-24.
40. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on agressive tumors. Cancer Causes control 1991;2(2):85-94.
41. Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willet WC, et al. A prospective study of intake of fish and marine fattyacids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12(1):64-67.
42. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4(7):505-518.
43. Cheetham PJ, Katz AE. La dieta y el cáncer de próstata un enfoque holístico a la gestión. Arch. Esp Urol 2011;64(8):720-734.
44. Bosire C, Stampfer MJ, Subar AF, Wilson KM, Park Y, Sinha R. Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control 2013;24(8):1527-1535.
45. Zhong S, Chen W, Yu X, Chen Z, Hu Q, Qhao J. Coffee consumption and risk of prostate cancer: an up-to-date meta-analysis. Eur J Clin Nutr 2013. http://www.nature.com/ejcn/journal/vaop/ncurrent/full/ejcn2013256a.html
46. Discacciati A, Orsini N, Andersson SO, Andrén O, Johansson JE, ;antzoros CS, et al. Coffee consumption and risk of localizad, advanced and fatal prostate cancer:a population-based prospective study. Ann Oncol 2013;24(7):1912-1918.
47. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. Effects of diet and exercise on insulina, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998;31(2):127-131.
48. Lustman A, Nakar S, Cohen AD, Vinjer S. Statin use and incident prostate cancer risk: does statin brand matter?. A population-based cohort study. Prostate Cancer Prostatic Dis. 2013. http://www.nature.com/pcan/journal/vaop/ ncurrent/full/pcan201334a.html